Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration.

Molteni R, Calabrese F, Pisoni S, Gabriel C, Mocaer E, Racagni G, Riva MA.

World J Biol Psychiatry. 2010 Mar;11(2):148-53. doi: 10.3109/15622970903447659.

PMID:
20109111
2.

Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

Descamps A, Rousset C, Millan MJ, Spedding M, Delagrange P, Cespuglio R.

Psychopharmacology (Berl). 2009 Jul;205(1):93-106. doi: 10.1007/s00213-009-1519-2. Erratum in: Psychopharmacology (Berl). 2009 Jul;205(1):175. Millan, Mark [corrected to Millan, Mark J].

PMID:
19370342
3.

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.

Millan MJ, Brocco M, Gobert A, Dekeyne A.

Psychopharmacology (Berl). 2005 Feb;177(4):448-58.

PMID:
15289999
4.

Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.

Norman TR, Cranston I, Irons JA, Gabriel C, Dekeyne A, Millan MJ, Mocaër E.

Eur J Pharmacol. 2012 Jan 5;674(1):27-32. doi: 10.1016/j.ejphar.2011.10.010.

PMID:
22040921
5.

Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.

Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, Gabriel C, Millan MJ, Mocaer E, Daszuta A.

Neuropsychopharmacology. 2009 Oct;34(11):2390-403. doi: 10.1038/npp.2009.72.

6.

Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.

Ladurelle N, Gabriel C, Viggiano A, Mocaër E, Baulieu EE, Bianchi M.

Psychopharmacology (Berl). 2012 Jun;221(3):493-509. doi: 10.1007/s00213-011-2597-5.

PMID:
22160164
7.
8.

Synergistic mechanisms involved in the antidepressant effects of agomelatine.

Tardito D, Molteni R, Popoli M, Racagni G.

Eur Neuropsychopharmacol. 2012;22 Suppl 3:S482-6. Review.

PMID:
22867907
9.

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.

Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, Sharp T, Daszuta A, Soumier A, Papp M, Rivet JM, Flik G, Cremers TI, Muller O, Lavielle G, Millan MJ.

Psychopharmacology (Berl). 2008 Sep;199(4):549-68. doi: 10.1007/s00213-008-1177-9.

PMID:
18523738
10.

Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.

Chagraoui A, Protais P, Filloux T, Mocaër E.

Psychopharmacology (Berl). 2003 Oct;170(1):17-22.

PMID:
12904965
11.

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.

Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D.

J Pharmacol Exp Ther. 2003 Sep;306(3):954-64.

12.

Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways.

Tardito D, Milanese M, Bonifacino T, Musazzi L, Grilli M, Mallei A, Mocaer E, Gabriel-Gracia C, Racagni G, Popoli M, Bonanno G.

BMC Neurosci. 2010 Jun 3;11:68. doi: 10.1186/1471-2202-11-68.

13.

Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain.

Zetterström TS, Pei Q, Madhav TR, Coppell AL, Lewis L, Grahame-Smith DG.

Neuropharmacology. 1999 Jul;38(7):1063-73.

PMID:
10428425
14.

Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.

Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, Tardito D.

World J Biol Psychiatry. 2011 Dec;12(8):574-87. doi: 10.3109/15622975.2011.595823. Review.

PMID:
21999473
15.

Influence of thyroid hormone on 5-HT(1A) and 5-HT(2A) receptor-mediated regulation of hippocampal BDNF mRNA expression.

Vaidya VA, Castro ME, Pei Q, Sprakes ME, Grahame-Smith DG.

Neuropharmacology. 2001;40(1):48-56.

PMID:
11077070
16.

Melatonergic drugs in clinical practice.

Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP.

Arzneimittelforschung. 2008;58(1):1-10. doi: 10.1055/s-0031-1296459. Review.

PMID:
18368944
17.

Noradrenergic and serotonergic blockade inhibits BDNF mRNA activation following exercise and antidepressant.

Ivy AS, Rodriguez FG, Garcia C, Chen MJ, Russo-Neustadt AA.

Pharmacol Biochem Behav. 2003 Apr;75(1):81-8.

PMID:
12759116
18.

Differential effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on BDNF mRNA expression in rat frontal cortex and hippocampus.

Martínez-Turrillas R, Moyano S, Del Río J, Frechilla D.

Neurosci Lett. 2006 Jul 10;402(1-2):126-30.

PMID:
16644117
19.

Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons.

Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM.

J Neurosci. 2000 Jan 1;20(1):8-21.

20.
Items per page

Supplemental Content

Support Center